The Relative Strength (RS) Rating for ACADIA Pharmaceuticals moved into a new percentile Monday, as it got a lift from 65 to 72.
This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks compares to other publicly traded companies.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating in the early stages of their moves. See if ACADIA Pharmaceuticals can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
While it's not currently an ideal time to buy shares, see if the stock goes on to establish and enter a buying range in heavy trade.
While revenue growth fell last quarter from 18% to 12%, EPS grew 207%, up from 0% in the prior report.
The company holds the No. 16 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Krystal Biotech and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
